FUNDAMENTAL AND CLINICAL EVALUATION OF KW-1070 IN THE FIELD OF UROLOGY

• Published in: CHEMOTHERAPY Vol. 29; no. Supplement2; pp. 566 - 581
• Main Authors: FUJII, TERUO, HAMAMI, MANABU, ARAKAWA, SOICHI, HIKOSAKA, KOJI, KAMIDONO, SADAO, ISHIGAMI, JOJI, ITO, NOBUO, ITO, HIROSHI, NAKANO, YASUHARU
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 25-10-1981
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.29.Supplement2_566

KW-1070, a new aminoglycoside antibiotic, was studied fundamentally and clinically. Antibacterial effects of KW-1070 against clinical isolates derived from urinary tracts were compared with those of GM, AMK and Netilmicin. KW-1070 was inferior to GM and Netilmicin and similar to AMK in antibacterial effects against E. coli, Klebsiella, Enterobacter, P. mirabilis and indole positive Proteus; against Serratia, similar to AMK and Netilmicin and inferior to GM by about onegrade of concentration; against P. aeruginosa, inferior to GM, AMK and Netilmicin by several grades. The bacteria resistant to GM, AMK and Netilmicin, of which MIC was more than 12.5μg/ml (inoculum size: 106 cells/ml), were respectively 21 (12%), 23 (13%) and (16%) strains among the strains determined on their antibacterial effects. The bacteria, against which MIC of KW-1070 was less than 6.25μg/ml, were respectively 10 (48%), 8 (35%) and 17 (59%) strains among the above resistant bacteria. 400-800mg. divided into two, KW-1070 was given by i. m. injection at a daily doses of for 5 days to 29 patients with complicated urinary tract infections. The clinical results were excellent in 7 cases, moderate in 16 cases, and unchanged in 6 cases. The effectiveness rate was 79.3%. Abnormal findings were not observed subjectively and objectively, including adverse effect on the cranial nerve VIII. As the abnormal value of the laboratory test, a transient increase of GOT and GPT was seen in 1 case given 800mg/day.